Introduction Dabigatran is effective and widely used to prevent ischemic stroke and systemic
embolism (SE) in patients with atrial fibrillation (AF). Chronic kidney disease (CKD) also has …

Introduction Dabigatran etexilate, a direct oral anti-coagulation agent, is used in the
prevention of thromboembolism in patients with non-valvular atrial fibrillation (NVAF) …

Background In clinical practice, physicians are given the choice of selecting one of two
dabigatran doses based on patient characteristics, with the lower dose typically used in …

Background/purpose Dabigatran is effective in preventing ischemic stroke and systemic
embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is …

Dabigatran etexilate is an oral direct thrombin inhibitor used in preventing thromboembolism
in patients with atrial fibrillation and several other conditions. Routine dabigatran …

Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in
patients with atrial fibrillation. In this study, we aimed to assess the associations between the …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Background Dabigatran etexilate (DE), an effective direct oral anticoagulant for patients with
atrial fibrillation (AF), should be carefully used in patients with renal insufficiency. Data on …

We read with interest the recent prospective observational study by Chan et al.[1] The
authors aimed to investigate the interpatient and intrapatient variabilities in dabigatran …